Produce less. Distribute it fairly. Create a greener world for all.

Nigeria’s Big Bet on Health Care

Nigeria’s dependence on imported medicines and medical equipment leaves families exposed to exchange-rate fluctuations and hospitals at the mercy of global supply chains. Expanding domestic manufacturing is essential to reducing the cost of treatment and ensuring that more Nigerians can access quality care.

Written by

Bola Ahmed Tinubu

–

in

–

Originally Published in

Project Syndicate

ABUJA—Nigeria should produce far more of the medicines and medical equipment its citizens need. Despite an established pharmaceutical industry, highly skilled health professionals, and a large domestic market, we remain heavily dependent on imported health products, and many Nigerians still travel abroad for treatment. More of what Nigerians spend on their health should support local businesses and jobs.

Worse, Nigeria’s dependence on imports exposes families to exchange-rate fluctuations that can put essential medicines beyond their reach, while leaving hospitals at the mercy of global supply chains. The Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC), which I established in October 2023, aims to address these problems by attracting domestic and international investment to Nigeria’s pharmaceutical industry and health-care sector.

PVAC is part of the Nigeria Health Sector Renewal Investment Initiative (NHSRII), which I launched in December 2023 to improve public-health services and emergency preparedness. The NHSRII involves federal and state authorities with development partners working toward a shared national objective and recognizing that investment in domestic manufacturing is as important as investment in clinics and hospitals.

A healthy population is the foundation of a productive economy. Illness impedes people’s ability to earn a living, while treatment costs can wipe out household savings. The government has a responsibility to reduce these costs, but it can’t do so through public spending alone. Manufacturers and investors need consistent policies and government institutions that work toward the same objectives before committing large sums to projects that may take years to reach commercial viability.

We have also taken steps to reduce domestic production costs. In June 2024, I signed an executive order that provides tax and tariff relief for equipment and inputs needed to manufacture health products. Between January 2025 and June of this year, my administration approved more than 24 billion naira ($17.7 million) in waivers for 75 manufacturers. These measures are intended to encourage investment and expansion, making essential medicines and treatments cheaper and more readily available.

Investments are already coming in. Ten new factories are currently being established across Nigeria, with work on six beginning in 2026. They will produce medicines, diagnostic tests, medical oxygen, and mosquito nets.

Production of mosquito nets is well underway. In September, roughly two years after reaching an agreement with PVAC, Vestergaard began operations at its Health Textiles Nigeria facility. Nigerian firm Harvestfield is also producing dual-ingredient insecticide-treated nets. At full capacity, the two companies are expected to produce more than ten million nets annually and employ more than 600 people.

For a country with one of the world’s heaviest malaria burdens, producing more mosquito nets at home means that millions of Nigerians will have access to lifesaving protection. As these businesses grow, local suppliers will benefit, and Nigerian workers will gain the technical expertise needed to produce more sophisticated products.

Nigeria should also produce more of the diagnostic tests our hospitals and clinics rely on. To this end, Nigerian firm Codix Bio reached an agreement with the Medicines Patent Pool, supported by the World Health Organization, to acquire technology from South Korea’s SD Biosensor, allowing it to manufacture rapid diagnostic tests. Abuja-based NASENI-Troment is already manufacturing diagnostic kits for malaria, HIV, hepatitis B and C, and COVID-19.

We welcome international investors willing to commit to long-term manufacturing in Nigeria. Our large, youthful population offers an attractive market for foreign companies, but we also want these investments to help Nigerian companies build the expertise they need to compete globally. As our manufacturing capacity grows, so, too, will our export earnings.

Our ambitions go beyond manufacturing. Nigerians should be able to obtain high-quality medical care in their own country. Investing in advanced diagnostics and specialist care would allow more Nigerians to receive treatment at home and give doctors and researchers the chance to develop their skills. For families dealing with cancer, this could mean avoiding costly trips abroad and the strain of being separated from loved ones.

But there is still a long way to go. Factories and health-care facilities cannot be built overnight, and it takes years to make them fully operational. Obviously, we cannot compromise on the quality and safety of medicines and medical devices made in Nigeria.

Investment in primary care and the planned expansion of health insurance can achieve only so much without a reliable supply of medicines and diagnostic tests. Medipool, Nigeria’s first nationally approved group purchasing organization, was established to coordinate orders and negotiate better prices for essential medicines and other health products. A more predictable market would encourage private investment while making better use of public funds.

The next step is to turn planned investments into operational factories and ensure that the medicines and medical devices they produce reach hospitals and clinics across Nigeria. This will require securing the necessary financing and removing the obstacles that hold up production, such as infrastructure deficits, regulatory bottlenecks, shortages of skilled manufacturing workers, limited market access, and unpredictable demand.

Meeting Nigeria’s considerable health-care needs could become a powerful growth engine. We have laid the foundation, but the real measure of our success will be whether Nigerians can afford the medicines they need and receive the quality of care they deserve.

Bola Ahmed Tinubu is President of the Federal Republic of Nigeria. Copyright: Project Syndicate, 2026. www.project-syndicate.org